0001161697-19-000508.txt : 20191127
0001161697-19-000508.hdr.sgml : 20191127
20191127170211
ACCESSION NUMBER: 0001161697-19-000508
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191127
FILED AS OF DATE: 20191127
DATE AS OF CHANGE: 20191127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: INGENITO GARY
CENTRAL INDEX KEY: 0001279473
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33057
FILM NUMBER: 191258843
MAIL ADDRESS:
STREET 1: 355 ALHAMBRA CIRCLE
STREET 2: SUITE 1500
CITY: CORAL GABLES
STATE: FL
ZIP: 33134
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001369568
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 355 ALHAMBRA CIRCLE
STREET 2: SUITE 1250
CITY: CORAL GABLES
STATE: FL
ZIP: 33134
BUSINESS PHONE: (305) 529-2522
MAIL ADDRESS:
STREET 1: 355 ALHAMBRA CIRCLE
STREET 2: SUITE 1250
CITY: CORAL GABLES
STATE: FL
ZIP: 33134
FORMER COMPANY:
FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC.
DATE OF NAME CHANGE: 20110215
FORMER COMPANY:
FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc.
DATE OF NAME CHANGE: 20060719
4
1
form4.xml
FORM 4 FOR 11-27-2019
X0306
4
2019-11-27
0
0001369568
CATALYST PHARMACEUTICALS, INC.
CPRX
0001279473
INGENITO GARY
355 ALHAMBRA CIRCLE, SUITE 1250
CORAL GABLES
FL
33134
0
1
0
0
Chief Medical Officer
Common stock, par value $0.001 per share
2019-11-27
4
M
0
100000
1.13
A
100000
D
Common stock, par value $0.001 per share
2019-11-27
4
S
0
100000
4.66
D
0
D
Options to purchase common stock
1.13
2019-11-27
4
M
0
100000
0
A
2024-01-03
Common Stock
100000
860000
D
Mr. Ingenito has advised the Company that his sale of shares was to raise funds for the purchase of a home by a family member and does not relate to any disagreements with the Company on any matter relating to the Company's operations, policies and practices. Mr. Ingenito remains an officer of the Company.
The option was granted on January 3, 2017 and previously vested in two equal annual installments.
/s/ Gary Ingenito
2019-11-27